Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema
2022
Abstrakt
Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death.
The aim of this study is to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks(LA).To our knowledge, this is the first direct comparison of these treatment approaches for LA.